{
  "guideline": {
    "id": "PA166104977",
    "name": "Annotation of DPWG Guideline for citalopram and CYP2C19",
    "source": "DPWG",
    "version": 34,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104977",
    "relatedChemicals": [
      {
        "id": "PA449015",
        "name": "citalopram",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299296",
      "name": "Recommendation PA166299296",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449015",
          "name": "citalopram",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061659,
        "html": "<p>Do not exceed the following daily doses:</p>\n<ol>\n<li>Adults up to 65 years: 30mg as tablets or 22mg as drops,</li>\n<li>Adults 65 years or older: 15mg as tablets or 10mg as drops</li>\n</ol>\n"
      },
      "implications": [
        "The risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased citalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the theoretically increased risk of QT prolongation will be offset."
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299295",
      "name": "Recommendation PA166299295",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449015",
          "name": "citalopram",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061658,
        "html": "<p>Do not exceed the following daily doses (50% of the standard maximum dose):</p>\n<ol>\n<li>adults up to 65 years: 20mg as tablets or 16mg as drops,</li>\n<li>Adults 65 years or older: 10mg as tablets or 8mg as drops</li>\n</ol>\n"
      },
      "implications": [
        "The risk of QT prolongation and therefore also the theoretical risk of torsades de pointes is increased as the gene variation leads to an increased citalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the increased risk of QT prolongation will be offset."
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299298",
      "name": "Recommendation PA166299298",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449015",
          "name": "citalopram",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061661,
        "html": "<p>The guideline does not provide a recommendation for citalopram in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on citalopram."
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299297",
      "name": "Recommendation PA166299297",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449015",
          "name": "citalopram",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061660,
        "html": "<p>No action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The gene variation increases conversion of citalopram to a weakly active metabolite. However, there is no significant effect on the plasma concentration of citalopram, the tolerance or the response."
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "34782755",
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.",
      "authors": [
        "Brouwer Jurriaan M J L",
        "Nijenhuis Marga",
        "Soree Bianca",
        "Guchelaar Henk-Jan",
        "Swen Jesse J",
        "van Schaik Ron H N",
        "Weide Jan van der",
        "Rongen Gerard A P J M",
        "Buunk Anne-Marie",
        "de Boer-Veger Nienke J",
        "Houwink Elisa J F",
        "van Westrhenen Roos",
        "Wilffert Bob",
        "Deneer Vera H M",
        "Mulder Hans"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2022
    },
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}